2. Search Result
Search Result
Results for "

MAP4K4 inhibitor

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-160623
    Rentosertib

    INS018_055; TNIK&MAP4K4-IN-2

    		 MAP4K TGF-beta/Smad Cadherin Interleukin Related Inflammation/Immunology
    Rentosertib (INS018 055) (compound 112) is the orally active TNIK and MAP4K4 inhibitor with IC50 values of 12-120, 12-120 nM, respectively .
    Rentosertib
  • HY-100343
    GNE-495
    Maximum Cited Publications
    10 Publications Verification

    		 MAP4K Cancer
    GNE-495 is a potent and selective MAP4K4 inhibitor with an IC50 of 3.7 nM.
    GNE-495
  • HY-19562
    PF-06260933
    4 Publications Verification

    		 MAP4K Inflammation/Immunology
    PF-06260933 is an orally active and highly selective inhibitor of MAP4K4 with IC50s of 3.7 and 160 nM for kinase and cell, respectively.
    PF-06260933
  • HY-111754
    DMX-5804
    4 Publications Verification

    		 MAP4K Cardiovascular Disease
    DMX-5804 is a potent, orally active and selective MAP4K4 inhibitor, with an IC50 of 3 nM, a pIC50 of 8.55 for human MAP4K4, less potent on MINK1/MAP4K6 (pIC50, 8.18), and TNIK/MAP4K7 (pIC50, 7.96). DMX-5804 enhances cardiomyocyte survival, and reduces ischemia-reperfusion injury in mice .
    DMX-5804
  • HY-125012
    MAP4K4-IN-3
    1 Publications Verification

    		 MAP4K Metabolic Disease
    MAP4K4-IN-3 (Compound 17) is a potent and selective MAP4K4 inhibitor with an IC50 of 14.9 nM in kinase assay, an IC50 of 470 nM in cell assay. Antidiabetic agent .
    MAP4K4-IN-3
  • HY-168972
    Famlasertib

    Prostetin/12k

    		 MAP4K Mixed Lineage Kinase Neurological Disease Inflammation/Immunology
    Famlasertib is a potent, brain-penetrant MAP4K inhibitor with IC50s value of 0.3 nM, 23.7 nM, and 44.7 nM for HGK (MAP4K4), MLK3, and MLK1, respectively. Famlasertib shows motor neuron protection and anti-inflammatory properties. Famlasertib can be used for the study of amyotrophic lateral sclerosis (ALS) .
    Famlasertib
  • HY-U00428A
    GNE 220 hydrochloride

    		MAP4K Cancer
    GNE 220 (hydrochloride) is a potent and selective inhibitor of MAP4K4, with an IC50 of 7 nM.
    GNE 220 hydrochloride
  • HY-156523
    TNIK&MAP4K4-IN-1

    		MAP4K Cancer
    TNIK&MAP4K4-IN-1 (compound A-39) is a dual inhibitor of TNIK and MAP4K4/HGK with IC50s of 1.29 nM and <10 nM，respectively，in human hepaticstellate cell LX-2. TNIK&MAP4K4-IN-1 can be used for cancer and fibrosis inhibition .
    TNIK&MAP4K4-IN-1
  • HY-132290
    TGFβRI-IN-3

    		TGF-β Receptor Inflammation/Immunology Cancer
    TGFβRI-IN-3 inhibits TGFβR1 at an IC50 of 0.79 nM with 2000-fold selectivity against MAP4K4. TGFβRI-IN-3 represents a highly selective TGFβR1 inhibitor that has potential applications in immuno-oncology .
    TGFβRI-IN-3
  • HY-19562A
    PF-06260933 hydrochloride
    4 Publications Verification

    		 MAP4K Inflammation/Immunology
    PF-06260933 hydrochloride is the hydrochloride form of PF-06260933 (HY-19562). PF-06260933 hydrochloride is an orally active and highly selective inhibitor of MAP4K4 with IC50s of 3.7 and 160 nM for kinase and cell, respectively .
    PF-06260933 hydrochloride
  • HY-U00428
    GNE 220

    		MAP4K Cancer
    GNE-220 is a potent and selective inhibitor of MAP4K4 with an IC50 of 7 nM.
    GNE 220
  • HY-162922
    MAP4K4-IN-6

    		MAP4K JNK Neurological Disease
    MAP4K4-IN-6 (Compound 15f) is a MAP4K4 inhibitor (IC50: 80 nM). MAP4K4-IN-6 reduces the c-Jun phosphorylation. MAP4K4-IN-6 has neuroprotective effects. MAP4K4-IN-6 increases the viability of motor neurons. MAP4K4-IN-6 can be used for research of Amyotrophic lateral sclerosis (ALS) .
    MAP4K4-IN-6
  • HY-178775
    PI4K-IN-3

    		PI4K Parasite MAP4K PI3K Infection
    PI4K-IN-3 (Compound 27) is an orally active PI4K inhibitor with an IC50 of 1.9  nM for Plasmodium vivax PI4K. PI4K-IN-3 has no hERG channel inhibition and mammalian cytotoxicity. PI4K-IN-3 has significant selectivity against the human MINK1 and MAP4K4 kinases but with low selectivity against human PI3Kα and PI4Kβ. PI4K-IN-3 has potent antimalarial activity and significantly reduces parasitaemia in NSG mice mouse models of Plasmodium falciparum malaria .
    PI4K-IN-3
  • HY-W003471
    Pyrrolo[2,1-f][1,2,4]triazin-4-amine

    		MAP4K Others
    Pyrrolo[2,1-f][1,2,4]triazin-4-amine is a MAP4K4 inhibitor with a surface plasmon resonance (SPR) Kd of 88 μM and a ligand efficiency of 0.56 .
    Pyrrolo[2,1-f][1,2,4]triazin-4-amine
  • HY-W402208
    MAP4K4-IN-7

    		MAP4K Neurological Disease Cancer
    MAP4K4-IN-7 (Compound 8) is a MAP4K4 inhibitor. MAP4K4-IN-7 shows moderate inhibitory activity against TNIK, MAP4K4, and MINK1 with pIC50 values of 6.8, 6.8, and 6.7 respectively. MAP4K4-IN-7 can be used for the researches of cancer and neurological disease, such as schizophrenia .
    MAP4K4-IN-7
  • HY-123965
    PF-06745013

    		MAP4K TNF Receptor Metabolic Disease Cancer
    PF-06745013 (Compound 37) is a MAP4K4 inhibitor without time-dependent inhibition (TDI) risk of CYP3A4 (IC50 of 0.4  nM for MAP4K4). PF-06745013 has no accumulation CNS-impaired and non-ATP competitive activities in mouse models. PF-06745013 can be used for inflammatory diseases like diabetes and cancers research .
    PF-06745013
  • HY-100343R
    GNE-495 (Standard)

    		MAP4K Reference Standards Cancer
    GNE-495 (Standard) is the analytical standard of GNE-495 (HY-100343). This product is intended for research and analytical applications. GNE-495 is a potent and selective MAP4K4 inhibitor with an IC50 of 3.7 nM.
    GNE-495 (Standard)
  • HY-W207224
    F1386-0303

    		MAP4K Cardiovascular Disease Inflammation/Immunology
    F1386-0303 is a highly selective MAP4K4 inhibitor with an IC50 of 34 nM against human targets. F1386-0303 exerts cardiomyocyte protective and function-preserving effects through mechanisms such as alleviating oxidative stress, inhibiting caspases, and maintaining mitochondrial membrane potential, while it does not interfere with the activity of Doxorubicin (HY-15142A) in cancer cells. F1386-0303 is rapidly cleared and has no bioavailability in mice, but it is well-suited as a tool compound for target validation. F1386-0303 can be applied to studies related to cardiac ischemia-reperfusion injury, Doxorubicin-induced cardiotoxicity, myocardial infarction and other related conditions .
    F1386-0303

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: